secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0001753926-24-000550
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chromocell appoints Frank Knuettel as permanent CEO, removing interim status
----------------------------------------------------------------------------

- Frank Knuettel appointed permanent CEO effective March 13, 2024; previously interim CEO since July 2023.
- Knuettel will continue as CFO, Treasurer, and Secretary of the company.
- He has raised over $300M in capital and managed 15+ M&A transactions during his career.
- Knuettel retains same compensation terms under existing amended consultant agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000175392624000550/0001753926-24-000550-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000175392624000550/g084130_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-000550

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer